Novavax Inc (WBO:NVAX)
€ 9.276 -0.09 (-0.96%) Market Cap: 1.49 Bil Enterprise Value: 734.28 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 47/100

Novavax Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 02:00PM GMT
Eric William Joseph
JPMorgan Chase & Co, Research Division - VP & Senior Analyst

All right. Good morning, and welcome to the 40th Annual JPMorgan Healthcare Conference. I'm Eric Joseph, senior biotech analyst with the firm. Thanks for joining us. Our next presenting company this morning is Novavax and here to talk to us about the company is CEO, Stan Erck. Quick programming note, there is a Q&A session after the presentation. Feel free to submit a question by clicking the "Ask a Question" icon. With that, Stan, thanks for joining us.

Stanley Charles Erck
Novavax, Inc. - President, CEO & Director

Eric, thank you very much, and thank you, everyone, for joining us this morning. I'm pleased to be here today to discuss the incredible progress Novavax has made over recent months as well as our many substantial milestones ahead in 2022. So let's turn to Slide 2. Before I begin today's presentation, I need to remind you that we will be making forward-looking statements during the conference, which are based on our current expectations. We encourage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot